CME vs MFG

CME Group trades near fair value with strong profitability and a dominant market position in financial derivatives, supported by a 58.95% profit margin and 63.39% operating margin—both well above sector averages. However, near-term revenue contraction (-3.0% YoY) and stagnant earnings growth (0.0% YoY) raise concerns about cyclical headwinds, while the P/E of 27.6x is above the sector average of 21.8x, limiting upside. Price momentum remains solid with a 1Y return of +33.3%, but insider selling and a 103.7% payout ratio signal caution. Analysts are unanimous in a 'hold' rating, aligning with our neutral stance given mixed fundamentals and valuation.

MFG presents a stark dichotomy between poor operational health (Piotroski F-Score: 2/9) and highly attractive valuation metrics. The stock is currently trading near its Graham Number ($8.22) and significantly below its growth-based intrinsic value ($15.64). While the company demonstrates strong earnings growth (16.4% YoY) and a compelling forward P/E of 6.06, the low F-Score suggests deteriorating fundamental trends that offset the valuation appeal. Consequently, the stock is a high-value play burdened by significant internal health warnings.